Bridget E. Bunner

Array ( [id] => 13622103 [patent_doc_number] => 20180362603 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-12-20 [patent_title] => METHODS AND COMPOSITIONS FOR REDUCING THE IMMUNOGENICITY OF CHIMERIC NOTCH RECEPTORS [patent_app_type] => utility [patent_app_number] => 16/010805 [patent_app_country] => US [patent_app_date] => 2018-06-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12497 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 10 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16010805 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16460797 [patent_doc_number] => 10844132 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-11-24 [patent_title] => Neutralizing antibodies and methods of use thereof [patent_app_type] => utility [patent_app_number] => 16/008998 [patent_app_country] => US [patent_app_date] => 2018-06-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 36 [patent_figures_cnt] => 90 [patent_no_of_words] => 29588 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 128 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16008998 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16460797 [patent_doc_number] => 10844132 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-11-24 [patent_title] => Neutralizing antibodies and methods of use thereof [patent_app_type] => utility [patent_app_number] => 16/008998 [patent_app_country] => US [patent_app_date] => 2018-06-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 36 [patent_figures_cnt] => 90 [patent_no_of_words] => 29588 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 128 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16008998 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16075627 [patent_doc_number] => 20200191800 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-06-18 [patent_title] => METHODS FOR TREATING DRUG RESISTANT CANCERS [patent_app_type] => utility [patent_app_number] => 16/622796 [patent_app_country] => US [patent_app_date] => 2018-06-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17736 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 83 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16622796 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14977927 [patent_doc_number] => 10442864 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-10-15 [patent_title] => Anti-Tie2 antibodies and uses thereof [patent_app_type] => utility [patent_app_number] => 16/007399 [patent_app_country] => US [patent_app_date] => 2018-06-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 7 [patent_no_of_words] => 14300 [patent_no_of_claims] => 7 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 45 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16007399 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13593335 [patent_doc_number] => 20180348216 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-12-06 [patent_title] => CD318 AS A MARKER FOR, AND CD318 INHIBITION AS A TREATMENT FOR, AUTOIMMUNE DISEASE [patent_app_type] => utility [patent_app_number] => 15/997248 [patent_app_country] => US [patent_app_date] => 2018-06-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10369 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15997248 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13590081 [patent_doc_number] => 20180346589 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-12-06 [patent_title] => MECHANO-ACTIVATED CONTROL OF GENE EXPRESSION [patent_app_type] => utility [patent_app_number] => 15/994330 [patent_app_country] => US [patent_app_date] => 2018-05-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 35355 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -24 [patent_words_short_claim] => 20 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15994330 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13840635 [patent_doc_number] => 20190023802 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-01-24 [patent_title] => ANTI-JAGGED1 ANTIGEN BINDING PROTEINS [patent_app_type] => utility [patent_app_number] => 15/993448 [patent_app_country] => US [patent_app_date] => 2018-05-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 39839 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -24 [patent_words_short_claim] => 13 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15993448 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15931207 [patent_doc_number] => 20200157237 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-05-21 [patent_title] => LYMPHOCYTE ANTIGEN CD5LIKE (CD5L) MONOMER, HOMODIMER, AND INTERLEUKIN 12B (P40) HETERODIMER ANTAGONISTS AND METHODS OF USE THEREOF [patent_app_type] => utility [patent_app_number] => 16/616536 [patent_app_country] => US [patent_app_date] => 2018-05-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 92492 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -43 [patent_words_short_claim] => 23 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16616536 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13400043 [patent_doc_number] => 20180251564 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-09-06 [patent_title] => Methods of Treatment by Administering an Anti-BAFFR Antibody Therapeutic Formulation [patent_app_type] => utility [patent_app_number] => 15/980411 [patent_app_country] => US [patent_app_date] => 2018-05-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17114 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -4 [patent_words_short_claim] => 91 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15980411 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15866313 [patent_doc_number] => 20200140560 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-05-07 [patent_title] => PROTEASE BASED SWITCH CHIMERIC ANTIGEN RECEPTORS FOR SAFER CELL IMMUNOTHERAPY [patent_app_type] => utility [patent_app_number] => 16/612280 [patent_app_country] => US [patent_app_date] => 2018-05-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17780 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -42 [patent_words_short_claim] => 24 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16612280 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13590015 [patent_doc_number] => 20180346556 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-12-06 [patent_title] => THERAPEUTIC COMBINATION AND METHODS OF TREATMENT WTIH A DLL4 ANTAGONIST AND AN ANTI-HYPERTENSIVE AGENT [patent_app_type] => utility [patent_app_number] => 15/966247 [patent_app_country] => US [patent_app_date] => 2018-04-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12931 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15966247 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14199017 [patent_doc_number] => 10266602 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-04-23 [patent_title] => Compositions and methods for diagnosis and treatment of hepatic cancers [patent_app_type] => utility [patent_app_number] => 15/964248 [patent_app_country] => US [patent_app_date] => 2018-04-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 38 [patent_figures_cnt] => 71 [patent_no_of_words] => 33171 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 38 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15964248 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15866201 [patent_doc_number] => 20200140504 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-05-07 [patent_title] => PEPTIDE FOR TOLL-LIKE RECEPTOR (TLR) INHIBITION AND PHARMACEUTICAL COMPOSITION COMPRISING SAME [patent_app_type] => utility [patent_app_number] => 16/610278 [patent_app_country] => US [patent_app_date] => 2018-04-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11624 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -10 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16610278 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16634333 [patent_doc_number] => 10912820 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-02-09 [patent_title] => Use of immunomodulatory kits for immunotherapeutic treatment of patients with myeloid leukemias [patent_app_type] => utility [patent_app_number] => 15/956343 [patent_app_country] => US [patent_app_date] => 2018-04-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 15 [patent_figures_cnt] => 15 [patent_no_of_words] => 8505 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 50 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15956343 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13490201 [patent_doc_number] => 20180296643 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-10-18 [patent_title] => SDF-1 FOR ANAL AND SPHINCTER WOUND HEALING [patent_app_type] => utility [patent_app_number] => 15/955221 [patent_app_country] => US [patent_app_date] => 2018-04-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18440 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 31 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15955221 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15527215 [patent_doc_number] => 20200055913 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-02-20 [patent_title] => HUMAN RESISTIN COMPOSITIONS AND METHODS OF TREATING TLR4-MEDIATED DISEASE AND INFECTION [patent_app_type] => utility [patent_app_number] => 16/498365 [patent_app_country] => US [patent_app_date] => 2018-04-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11802 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 32 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16498365 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15527215 [patent_doc_number] => 20200055913 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-02-20 [patent_title] => HUMAN RESISTIN COMPOSITIONS AND METHODS OF TREATING TLR4-MEDIATED DISEASE AND INFECTION [patent_app_type] => utility [patent_app_number] => 16/498365 [patent_app_country] => US [patent_app_date] => 2018-04-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11802 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 32 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16498365 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16665131 [patent_doc_number] => 10934364 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-03-02 [patent_title] => Method for in vivo expansion of T regulatory cells [patent_app_type] => utility [patent_app_number] => 15/950962 [patent_app_country] => US [patent_app_date] => 2018-04-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 22 [patent_figures_cnt] => 1 [patent_no_of_words] => 19517 [patent_no_of_claims] => 3 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 60 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15950962 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15931761 [patent_doc_number] => 20200157514 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-05-21 [patent_title] => Polypeptide Set to Be Used in Light Dependent Gene Recombination [patent_app_type] => utility [patent_app_number] => 16/604351 [patent_app_country] => US [patent_app_date] => 2018-04-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15682 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 201 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16604351 [rel_patent_id] =>[rel_patent_doc_number] =>)